NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Active:	No
Cancer Type:	Melanoma	NCT ID:	NCT05340621
Trial Phases:	Phase I Phase II	Protocol IDs:	OKI-179-230 (primary) NCI-2022-05165
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	OnKure, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT05340621

Summary

The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with
activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated
Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the
MEK inhibitor binimetinib.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.